P/E ratio for Dechra Pharmaceuticals (DPH.L)
P/E ratio at the end of 2022: 66.4
According to Dechra Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 7540.05. At the end of 2022 the company had a P/E ratio of 66.4.
P/E ratio history for Dechra Pharmaceuticals from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 66.4 | -13.17% |
| 2021 | 76.4 | -13.7% |
| 2020 | 88.6 | -1.36% |
| 2019 | 89.8 | 27.22% |
| 2018 | 70.6 | 21.63% |
| 2017 | 58.0 | -23.44% |
| 2016 | 75.8 | 115.75% |
| 2015 | 35.1 | 341.73% |
| 2014 | 7.95 | -71.96% |
| 2013 | 28.4 | 14.77% |
| 2012 | 24.7 | 26.5% |
| 2011 | 19.5 | 24.58% |
| 2010 | 15.7 | -16.95% |
| 2009 | 18.9 | 3.92% |
| 2008 | 18.2 | 42.32% |
| 2007 | 12.8 | 14.38% |
| 2006 | 11.2 | 4.99% |
| 2005 | 10.6 | 3.06% |
| 2004 | 10.3 | 21.76% |
| 2003 | 8.47 | -27.08% |
| 2002 | 11.6 | -55.77% |
| 2001 | 26.3 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.